诺维本为主的联合动静脉给药治疗晚期非小细胞肺癌的临床分析

The Clinical Analysis of NVB Based Combination Chemotherapy by Arterial and Venous Administration in Advanced NSCLC

[目的]探讨诺维本为主联合化疗方案支气管动脉结合静脉给药治疗晚期肺癌的疗效及毒副作用。[方法]32例非小细胞肺癌 ,其中Ⅲ期28例 ,Ⅳ期3例 ,化疗方案以MMC8mg,NVB40mg,CDDP80mg～100mg,d1 支气管动脉灌注 ,NVB40mg,d8 静脉给药 ,每疗程间隔21日～28日 ,2个疗程评价疗效。[结果]总缓解率为65.8 % ,其中CR1例、PR20例、SD9例 ,主要毒副作用为骨髓抑制。[结论]以MMC +NVB

To evaluate the therapeutic effect and side effect of combined MMC,NVB and CDDP chemotherapy for advanced non_small cell lung Cancer (NSCLC).Thirty_two cases with advanced NSCLC were treated with MMC+NVB+CDDP by way of bronchial artery infusion(BAI).Two therapeutic courses were given with an interval of 21 to 28 days.There was one case complete response in patients treated with the regimen,partial respones was observed in 20 of 32 cases.Side effects were mainly myelo suppression and digestive tract toxicity.[Conclusion]It's thought that the combined chemotherepy with MMC+NVB+CDDP by BAI and vein administration is effective and tolerantin advance NSCLC.